

Reference:	FOI.17105.25
Subject:	New biologic and targeted medications
Date of Request:	15 April 2025

Requested:

1. How many patients were treated in March 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- Etrasimod
- Filgotinib
- Golimumab
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab (Stelara)
- Ustekinumab Biosimilar
- Vedolizumab

2. How many patients were treated in March 2025 (or latest available month) for Crohn's disease with the following biologic drugs?

- Golimumab
- Risankizumab
- Upadacitinib
- Ustekinumab (Stelara)
- Ustekinumab Biosimilar
- Vedolizumab

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the "appropriate limit" as stated in the Freedom of Information Act 2000 and the Data Protection (Appropriate Limit and Fees) Regulations 2004. The "appropriate limit" represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for question 2, the UHB would need to undertake a manual trawl of all identified prescriptions and cross reference with the patient's medical record to identify the reason for treatment.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority's obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, the UHB has a duty to provide advice and assistance. Therefore, the UHB provides the accessible information it holds below.

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB provides, within the table overleaf, the number of patients that were issued with the named biologic medications, by the Gastroenterology Department, during March 2025.

Medication	Number
Etrasimod	0
Filgotinib	*
Golimumab	0
Mirikizumab	*
Ozanimod	0
Risankizumab	35
Tofacitinib	*
Upadacitinib	23
Ustekinumab (Stelara)	*
Ustekinumab Biosimilar	37
Vedolizumab	56

2. A Section 12 exemption has been applied. However, under Section 16 the UHB provides, within the table below, the number of patients treated with the named biologic medications for any condition, during March 2025.

Medication	Number
Golimumab	13
Risankizumab	65
Upadacitinib	45
Ustekinumab (Stelara)	*
Ustekinumab Biosimilar	49
Vedolizumab	94